ImmunityBio, Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own79.16% Shs Outstand403.64M Perf Week7.00%
Market Cap588.36M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float83.44M Perf Month-50.67%
Income-416.60M PEG- EPS next Q-0.27 Inst Own10.30% Short Float / Ratio27.38% / 7.88 Perf Quarter-76.41%
Sales0.20M P/S2941.79 EPS this Y-16.90% Inst Trans16.60% Short Interest22.85M Perf Half Y-72.42%
Book/sh-1.11 P/B- EPS next Y-3.00% ROA-117.10% Target Price9.00 Perf Year-74.33%
Cash/sh0.25 P/C5.49 EPS next 5Y-1.70% ROE102.30% 52W Range1.21 - 7.80 Perf YTD-70.03%
Dividend- P/FCF- EPS past 5Y-13.40% ROI-152.20% 52W High-80.52% Beta1.47
Dividend %- Quick Ratio0.30 Sales past 5Y39.80% Gross Margin- 52W Low25.57% ATR0.24
Employees725 Current Ratio0.30 Sales Q/Q-75.00% Oper. Margin- RSI (14)23.43 Volatility15.97% 13.69%
OptionableYes Debt/Eq- EPS Q/Q-16.70% Profit Margin- Rel Volume0.92 Prev Close1.35
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.90M Price1.52
Recom1.50 SMA20-21.64% SMA50-53.57% SMA200-65.73% Volume230,598 Change12.55%
Aug-03-22Initiated Jefferies Buy $8
Feb-16-23 09:00AM
Feb-15-23 09:00AM
Jan-19-23 09:00AM
Dec-12-22 08:30AM
Nov-17-22 09:00AM
05:21PM Loading…
Nov-10-22 05:21PM
Oct-27-22 08:00AM
Jul-28-22 04:18PM
Jul-26-22 04:17PM
Jun-30-22 10:00AM
Jun-14-22 11:25AM
Jun-06-22 09:00AM
May-23-22 08:32AM
May-16-22 07:29AM
Apr-28-22 09:00AM
09:00AM Loading…
Apr-25-22 09:00AM
Apr-01-22 04:15PM
Mar-02-22 09:00AM
Feb-21-22 09:32AM
Feb-18-22 12:13PM
Feb-15-22 09:00AM
Feb-14-22 05:17PM
Jan-31-22 07:16PM
Jan-21-22 09:38PM
Jan-19-22 07:34AM
Jan-18-22 06:00PM
Jan-13-22 09:00AM
Jan-12-22 08:30AM
09:00AM Loading…
Jan-04-22 09:00AM
Jan-03-22 08:00AM
Dec-20-21 09:00AM
Dec-07-21 06:38AM
Nov-18-21 09:00AM
Nov-08-21 05:14PM
Nov-04-21 09:00AM
Oct-19-21 09:00AM
Oct-13-21 09:00AM
Oct-04-21 08:30AM
Sep-13-21 08:30AM
Sep-07-21 08:30AM
Sep-01-21 09:00AM
Aug-16-21 09:00AM
Jul-27-21 09:00AM
Jul-14-21 09:00AM
Jun-28-21 09:00AM
Jun-23-21 04:05PM
Jun-15-21 07:00AM
Jun-10-21 09:00AM
May-25-21 09:00AM
May-24-21 09:00AM
May-20-21 09:00AM
May-17-21 09:00AM
May-04-21 09:00AM
Apr-29-21 09:00AM
Apr-22-21 09:00AM
Apr-08-21 09:00AM
Apr-01-21 09:00AM
Mar-29-21 09:00AM
Mar-26-21 03:04PM
Mar-22-21 09:00AM
Mar-15-21 09:00AM
Mar-11-21 09:00AM
Mar-10-21 09:00AM
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Adcock RichardCEO & PresidentFeb 05Option Exercise0.0083,3330227,774Feb 07 06:23 PM
Adcock RichardCEO & PresidentDec 31Option Exercise0.008,6200148,714Jan 04 09:48 PM
Sachs David C.Chief Financial OfficerDec 31Option Exercise0.007,598051,298Jan 04 09:49 PM